Blog

12 Articles

circular flashes of red yellow and green light against a black background
Research
May 26, 2022 • 3 Min

Chemotherapy-Radiation Combination for Pancreatic Cancer in the Liver

Can targeted radiation disrupt tumor growth in the liver of advanced pancreatic cancer patients with BRCA2 and PALB2 mutations?

long-term pancreatic cancer survivor Elizabeth O'Connor and her family
Survivor Stories
April 11, 2022 • 6 Min

Cherishing the Simple Things

Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.

Kim Reiss Binder
Research
January 12, 2022 • 5 Min

New Study Aims to Reduce Recurrence Risk for Select Patients

Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.

abstract DNA image in bright greens and reds
Research
May 25, 2021 • 2 Min

PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations

A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.

DNA aqua pipette
Research
February 26, 2020 • 6 Min

Exploiting DNA Mutations For Pancreatic Cancer Treatment

Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.

glass test tubes in a cluster
Research
October 22, 2019 • 2 Min

Searching for Potential Pancreatic Cancer Blood Biomarkers

Researchers are using blood samples to follow people considered at risk for developing pancreatic cancer in a trial looking for early detection biomarkers.

Gloria Peterson, Ph.D.
Research
February 4, 2019 • 5 Min

Genetic Testing for All Pancreatic Cancer Patients

A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.

Kim Reiss Binder
Research
November 1, 2018 • 5 Min

PARP Inhibitors for Pancreatic Cancer Maintenance Treatment

Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.

DNA representation
Research
December 5, 2017 • 5 Min

The ABCs of Genetic Testing

There are a number of different genetic mutations that can cause familial pancreatic cancer. This article explains some of the most common ones.

Gloria Peterson, Ph.D.
Research
October 12, 2017 • 5 Min

Tumor Genetics Research Brings Some Answers for Families at High Risk

Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.

Illustration of a protein that includes the BRCA2 mutation. The illustration includes spirals in brown, strands in purple, blue directional arrows, and green, yellow, red, and blue circles.
Research
June 27, 2017 • 2 Min

A Maintenance Trial for Patients with BRCA or PALB2 Mutations

A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.

Microscopy image of a tumor section (obtained from a mouse tumor model) shows the blue-stained nanoparticles selectively accumulating in the peripheral tumor area and then penetrating into tumor cells
Research
August 18, 2016 • 2 Min

Exploring the Effectiveness of an Experimental Class of Drug

Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?